Clinical HIV-1 eradication studies
|
|
- Benjamin Parrish
- 5 years ago
- Views:
Transcription
1 Clinical HIV-1 eradication studies Mathias Lichterfeld, M. D., Ph. D. Massachusetts General Hospital Harvard Medical School No disclosures
2 HIV-1 persistence despite HAART Blood Tissue HIV RNA (cps/ml) 50 >10 years Cell associated HIV DNA Cell associated HIV RNA Cell associated HIV DNA Infectious virus (IUPM) Plasma single copy assay Years on cart Slide courtesy of Javier Martinez-Picado/Sharon Lewin
3 Latent and replicative HIV-1 infection in CD4 T cells Activated CD4+ T cell cart Resting CD4+ T cell Survival (long-half life) Homeostatic proliferation Slide courtesy of Javier Martinez-Picado/Sharon Lewin Eckstein, Immunity 2001; Swiggard, J Virol 2005; Saleh, Blood 2007; Marini, J Immunol 2008; Bosque, Blood 2009; Cameron, PNAS 2010; Lassen, PLoS One 2012
4 Clinical HIV-1 eradication strategies Ex-vivo gene editing/gene therapy to reduce viral co-receptor expression, followed by adoptive immunotherapy of HIV-1 resistant cells Bone marrow/hsc transplantation with CCR5-negative grafts Combination of latency reversing agents with immune mediated interventions ( kick and kill )
5 Pharmacological latency-reversing agents Shock component HDACi Panobinostat Romidepsin Vorinostat HMTi EZH2 inhibitors PKC activators Prostratin Didier Trono et, al. Science 2010 DNA methylation Inhibitors
6 Immune-mediated interventions kill component Vaccines designed to induce effector T cell responses Broadly-neutralizing antibodies, possibly labeled with Immunotoxins etc. Activators of innate immunity Immunoregulatory interventions (i. e. PD-1 inhibitors etc)
7 HDACi turn HIV-1 transcription on HDACi DNA nucleosomes OFF TF Bolden, Nat Rev Drug Disc 2006; Prince. Clin Canc Res 2009; Contreras, J Biol Chem 2009; Archin AIDS Res Hum Retrovir 2009; Reuse, PLoS One 2009; Burnett, J Virol 2010 Slide courtesy of Javier Martinez-Picado/Sharon Lewin
8 Clinical studies with HDACi Vorinostat (Merck) Romidepsin (Celgene/Gilead) Panobinostat (Novartis) Ex-vivo HIV-1 reactivation weaker strong strong Dose, dosing schedule and formulation 400mg p. o. Single-dose (Archin et al, Nature 2012) three consecutive doses per week for eight weeks (Archin et al, JID 2014) daily for 14 days (Elliott et al, CROI 2013) 5mg/m 2 i. v. singledose infusion (Aarhus) 0.5/2/5mg/m 2 (ACTG) 20mg p. o. TIW (M, W, F) QOW Rasmussen et al, Lancet HIV 2014 Pilot clinical trials completed in process completed (Aarhus) in HAART-treated HIV patients (UNC, Melbourne) (ACTG, Aarhus)
9 Clinical studies with Vorinostat (Saha) Single dose vorinostat led to a 4.8- fold increase in cell-associated HIV RNA. No significant increases in HIV-1 RNA during repetitive dosing No change in HIV-1 DNA Multiple dose vorinostat led to a mean 2.5-fold increase in cell-associated HIV RNA in total CD4+ T cells. No effect on CD4 T cell-associated HIV-1 DNA or plasma HIV-1 RNA Elliott/Lewin, CROI 2013 Archin et al, Nature 2012 and JID 2014
10 Romidepsin Licensed in US for treatment of PTCL and CTCL Can reactive HIV-1 in ex-vivo assays (Wei et al, Plos Path 2014) Currently being tested in RCT (ACTG5315) (single dose at 0.5mg/m 2, 2mg/m 2, 5mg/m 2 ) In vivo evaluation in a non-randomized trial in six patients (Sogaard et al, IAS 2014) Romidepsin (5 mg/m 2 ) iv on day 0, 7, and 14 Endpoints: Safety, cell-associated HIV RNA, plasma HIV RNA Self-reported AEs: Total of 40, 36 related to RMD. Most common: Nausea, vomiting, diarrhea, abdominal pain Fatigue All self-resolving, none with > grade 2
11 Cell-associated HIV-1 RNA during treatment with Romidepsin Sogaard et al, IAS 2014
12 Plasma HIV-1 RNA during treatment with Romidepsin Viral load: COBAS TaqMan HIV-1 Test, v2.0 TMA: Qualitative NAT screening system (PROCLEIX ULTRIO Plus, Genprobe) Sogaard et al, IAS 2014
13 Cell-associated HIV-1 DNA during treatment with Romidepsin Sogaard et al, IAS 2014
14 Panobinostat (LBH589) A hydroxamic acid pan-hdac inhibitor Developed by Novartis for the treatment of multiple myeloma (approval expected in 2014) Dosed mg TIW or TIW QOW Inhibitory activity in the lower nm range against HDACs 1, 2 and 3 which appear important to maintaining HIV latency Panobinostat induced HIV production in latently infected cell lines and primary T cells with high potency Huber et al J Biol Chem Keedy et al Journal of Virology Archin et al AIDS Rasmussen et al 2013, HVI
15 Overall study design Blood draws Twice at baseline Twice every treatment cycle and once every pause week (13 times during panobinostat treatment) 12 and 32 weeks after panobinostat initiation Lumbar puncture and sigmoid biopsies before and during the last treatment cycle
16 Safety adverse events A total of 16 AEs presumed related to panobinostat (all CTCAE grade 1) 10/15 patients experienced AEs presumed related to panobinostat Fatigue the most frequent AE (experienced by 7/15 patients) All completed full panobinostat dosing and follow-up Rasmussen et al, Lancet HIV 2014
17 Cell-associated unspliced HIV RNA (CA US HIV-RNA) Measured in total CD4+ T cells using semi-nested qpcr (quadruplicates) A highly statistically significant increase over time (repeated measurement ANOVA; P<0.0001) Rapid increase only 2 hours after first dose Significant increases on all time points Median maximal increase of 3.5 (range ) Rasmussen et al, Lancet HIV 2014
18 HIV-1 plasma viremia during treatment with panobinostat Transcription mediated amplification (TMA)-based detection of HIV RNA: 50% analytic sensitivity to detect 3.8 copies/ml 95% analytic sensitivity to detect 12 copies/ml Only 1/15 remained undetectable at all time points during panobinostat treatment 4/15 patients positive at all time points (make up 8/9 positive baseline values) 9/15 negative at both baseline samples and became positive during panobinostat treatment Rasmussen et al, Lancet HIV 2014
19 Total cell-associated HIV-1 DNA during treatment with panobinostat Measured per 10 6 CD4+ T cells using ddpcr Decrease from baseline to day 14 (end of first treatment cycle) Overall no decline in total HIV DNA from baseline to week 12 (4 weeks post treatment) Rasmussen et al, Lancet HIV 2014
20 Total cell-associated HIV-1 DNA during treatment with panobinostat 4/15 patients displayed sustained reductions in total HIV DNA No difference in nadir CD4, baseline CD4 or baseline HIV DNA
21 Total HIV DNA during panobinostat treatment post-hoc analysis
22 Change in HIV-1 DNA during treatment with panobinostat correlates with kinetics of viral rebound during ATI plasma viral load (copies/ml) time after treatment interruption (days) 9/15 patients agreed to participate in ATI, including three responder patients No association between baseline characteristics and viral rebound during ATI Rasmussen et al, Lancet HIV 2014
23 Expansion of HIV-1-specific CTL during Panobinostat treatment Magnitude Breadth 2000 p= p=0.01 total magnitude of HIV-1-specific CTL (SFC/million PBMC) total breadth of HIV-1-specific CTL (no of responses) before treatment after treatment 0 before treatment after treatment Screening for CTL with library of optimal CTL epitopic peptides (IFN-γ Elispot)
24 HIV-1-specific CTL are not associated with HIV-1 DNA changes during panobinostat treatment Interferon-γ TNF-α FC HIV-1-specific effector CTL FC HIV-1 DNA (log10) FC HIV-1-specific effector CTL FC HIV-1 DNA (log10) no associations between CTL magnitude or breadth and HIV-1 DNA levels also no associations between protective HLA class I alleles and HIV-1 DNA levels
25 Expression patterns of Interferon-stimulated genes correlate with HIV-1 DNA decrease during treatment with panobinostat
26 HIV-1 DNA decrease during panobinostat treatment occurs preferentially in carriers of IL28B CC carriers Fold change in total HIV-1 DNA p= CC CT IL-28B
27 Changes in HIV-1 DNA during panobinostat treatment are correlated to changes in NK cells FC in CD69+ NK cells Week 2 Week 6 Week 8 (end of study) rho:-0.66; p= FC in HIV-1 DNA (log10) FC in CD69+ NK cells rho:-0.56; p= FC in HIV-1 DNA (log10) FC in CD69+ NK cells rho:-0.64, p= FC in HIV-1 DNA (log10)
28 Changes in HIV-1 DNA during panobinostat treatment are correlated with changes in NK cells
29 Changes in HIV-1 DNA during treatment with IFN-a/RBV in HIV/HCV co-infected patients 10 5 p= HIV-1 DNA copies/10 6 CD4+ T cells pre-ifn post-ifn
30 Conclusions HDACi can increase HIV-1 transcription in CD4 T cells from ART-treated patients Viral reactivation with RMD and PBT leads to transient increases of plasma RNA All HDACi have an acceptable safety profile in ART-treated patients No significant changes in HIV-1 DNA during HDACi treatment on population level Some patients during treatment with PBT and RMA have substantial decline of HIV-1 DNA Patients with reduction of HIV-1 DNA during PBT treatment differ in IL-28B CC GT ISG expression patterns Innate effector cell activity Kinetics of viral rebound during ATI
31 Acknowledgments Department of Infectious Diseases, Aarhus University Hospital Thomas Rasmussen, MD Ole Schmeltz Søgaard, MD, PhD Martin Tolstrup, MSc, PhD Lars Østergaard, Professor/Head, MD, DMSc, PhD Christel Rothe Brinkmann, MSc, PhD Rikke Olesen, MD, PhD Anni Winckelmann and Ann-Sofie Kjer Lene Svinth Jøhnke and Erik Hagen Nielsen Department of Infectious Diseases, Alfred Hospital, Melbourne Sharon Lewin, Professor/Head, PhD Ajantha Solomon, BSc Massachusetts General Hospital, Ragon Institute, Boston Maria Buzon, MSc, PhD Selena Vigano, PhD Westmead Millennium Institute for Medical Research, Sydney Sarah Palmer, PhD University of Colorado, School of Medicine Charles A. Dinarello, Professor of Medicine and Immunology
Towards an HIV Cure. Steven G. Deeks Professor of Medicine University of California, San Francisco
Towards an HIV Cure Steven G. Deeks Professor of Medicine University of California, San Francisco Why are we now talking about a cure? Emerging recognition that HAART does not fully restore health and/or
More informationApproaching a Cure Daniel R. Kuritzkes, MD
Approaching a Cure Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosures The speaker is a consultant and/or has received speaking honoraria
More informationIAS 2013 Towards an HIV Cure Symposium
Entinostat is a histone deacetylase (HDAC) inhibitor selective for class 1 HDACs and activates HIV production from latently infected primary T-cells Fiona Wightman Monash University, Melbourne, Australia
More informationWith over 20 drugs and several viable regimens, the mo6vated pa6ent with life- long access to therapy can control HIV indefinitely, elimina6ng the
Towards an HIV Cure Steven G. Deeks, MD Professor of Medicine in Residence HIV/AIDS Division University of California, San Francisco (UCSF) WorldMedSchool; July 22, 2013 1 With over 20 drugs and several
More informationMHRP. Outline. Is HIV cure possible? HIV persistence. Cure Strategies. Ethical and social considerations. Short video on patients perspectives on cure
Outline Is HIV cure possible? Ø HIV persistence Cure Strategies Ethical and social considerations Short video on patients perspectives on cure A Case of Cure Off ART Treatment Mechanism Lesson The Berlin
More informationPROSPECTS FOR HIV CURE IN ADULTS. Nov 11 th 2013 John Frater
PROSPECTS FOR HIV CURE IN ADULTS FIS 2013 Nov 11 th 2013 John Frater April 29 th 2013; Telegraph online THE COMPONENTS OF A CURE. What is cure? Issues to consider: Post treatment control the benefit of
More informationCan HIV be cured? (how about long term Drug free remission?)
Can HIV be cured? (how about long term Drug free remission?) Shirin Heidari International AIDS Society EC Think Tank meeting 27-28 October 2010 Luxemburg HAART can control HIV, cannot eradicate it Life
More informationState of the ART: HIV Cure where are we now and. where are we going? Jintanat Ananworanich, MD, PhD MHRP
State of the ART: HIV Cure where are we now and ì where are we going? Jintanat Ananworanich, MD, PhD Associate Director for Therapeu1cs Research US Military HIV Research Program (MHRP) Maryland, USA Deputy
More informationDr Jintanat Ananworanich
BHIVA AUTUMN CONFERENCE 2014 Including CHIVA Parallel Sessions Dr Jintanat Ananworanich US Military HIV Research Program in Bethesda Maryland, USA 9-10 October 2014, Queen Elizabeth II Conference Centre,
More informationRecent Insights into HIV Pathogenesis and Treatment: Towards a Cure
Recent Insights into HIV Pathogenesis and Treatment: Towards a Cure Deborah Persaud, M.D. Associate Professor Department of Pediatrics Division of Infectious Diseases Johns Hopkins University School of
More informationHIV Cure Update. Christine Durand, MD 14 de abril de 2016, XIII Conferência Brasil Johns Hopkins University em HIV/AIDS
HIV Cure Update Christine Durand, MD 14 de abril de 2016, XIII Conferência Brasil Johns Hopkins University em HIV/AIDS Financial Disclosures Research grants paid to my institution: Gilead Sciences, Bristol
More informationEradication of HIV Bonaventura Clotet Hospital Universitàri Germans Trias i Pujol Badalona. Barcelona. Catalonia
Eradication of HIV Bonaventura Clotet Hospital Universitàri Germans Trias i Pujol Badalona. Barcelona. Catalonia Dr Bonaventura Clotet Transparency declaration I have served during the past 2 years as
More informationT Memory Stem Cells: A Long-term Reservoir for HIV-1
Towards an HIV Cure Pre-Conference Symposium 20 & 21 July 2012 T Memory Stem Cells: A Long-term Reservoir for HIV-1 Maria J Buzon, PhD Ragon Institute of MGH, MIT and Harvard, Massachussetts General Hospital,
More informationIAS 2015 Towards an HIV Cure symposium Vancouver Immune recognition following latency reversal
IAS 2015 Towards an HIV Cure symposium Vancouver Immune recognition following latency reversal Marcus Altfeld Professor of Medicine Outline Immune recognition of HIV-1-infected cells Kinetics of antigen
More informationArticles. Funding The Danish Council for Strategic Research and Aarhus University.
Panobinostat, a histone deacetylase inhibitor, for latentvirus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial Thomas A Rasmussen,
More informationImpact of Vorinostat Treatment of Non- Hodgkin s Lymphoma on HIV-1 Latent Reservoir
Impact of Vorinostat Treatment of Non- Hodgkin s Lymphoma on HIV-1 Latent Reservoir Adam Capoferri, Juan Carlos Ramos, Daniel Xu, Daniel I.S. Rosenbloom, Janet D. Siliciano, Robert F. Siliciano, Ariela
More informationTherapeutic Immunization with Autologous DC Pulsed with Autologous Inactivated HIV-1 Infected Apoptotic Cells
Therapeutic Immunization with Autologous DC Pulsed with Autologous Inactivated HIV-1 Infected Apoptotic Cells Sharon A. Riddler, MD, MPH University of Pittsburgh May 2008 Slide 1 HIV and DC Vaccines During
More informationCTLA-4-expressing CD4 T cells are critical contributors to SIV viral persistence
IAS 2015 Towards an HIV Cure symposium Vancouver CTLA-4-expressing CD4 T cells are critical contributors to SIV viral persistence Colleen McGary Paiardini lab Emory University HIV reservoir prevents eradication
More informationHow HIV Causes Disease Prof. Bruce D. Walker
How HIV Causes Disease Howard Hughes Medical Institute Massachusetts General Hospital Harvard Medical School 1 The global AIDS crisis 60 million infections 20 million deaths 2 3 The screen versions of
More informationProfessor Jonathan Weber
HIV/AIDS at 30: Back to the Future BHIVA / Wellcome Trust Multidisciplinary Event to mark World AIDS Day 2011 British HIV Association (BHIVA) 2011 HIV/AIDS at 30: Back to the Future BHIVA / Wellcome Trust
More informationHacia la Curación del VIH
Jornadas 2012 Actualización en Atención Farmacéutica al Paciente Con Patologías Víricas Hacia la Curación del VIH Santiago Moreno Servicio de Enfermedades Infecciosas Hospital Ramón y Cajal Madrid HIV
More informationCROI 2016 Review: Immunology and Vaccines
Frontier AIDS Education and Training Center CROI 2016 Review: Immunology and Vaccines Meena Ramchandani MD MPH Acting Instructor, University of Washington March 2016 This presentation is intended for educational
More informationCurrent Clinical Therapies for HIV Remission. David Margolis MD UNC HIV Cure Center
Current Clinical Therapies for HIV Remission David Margolis MD UNC HIV Cure Center Aiming for sustained remission off ART Cohen J. Science 214 Luzuriaga et al. NEJM 3;8: 786 Effect of vorinostat, hydroxychloroquine
More informationHIV Eradication and the Quest for Functional Cure
HIV Eradication and the Quest for Functional Cure Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosures Consultant and/or research support
More informationBeyond HAART: Outline. HIV-1 Time Line. Outline. Approaches to HIV Eradication 8/15/2013
8/5/203 Beyond HAART: Approaches to HIV Eradication I have no financial conflicts of interest to disclose 8 August 203 Adam Spivak MD Visiting Instructor, Division of Infectious Diseases University of
More informationHIV remission: viral suppression in the absence of ART. Sarah Fidler Brian Gazzard Lecture BHIVA 2016
HIV remission: viral suppression in the absence of ART Sarah Fidler Brian Gazzard Lecture BHIVA 2016 Disclosures: My institution receives funding for research from MSD, GSK, ViiV, Gilead Summary of talk
More information5/11/2017. HIV Cure Research Questions and a Few Answers
HIV Cure Research Questions and a Few Answers Steven G. Deeks, MD Professor of Medicine University of California San Francisco San Francisco, California FORMATTED: 04/13/17 Financial Relationships With
More informationInduction and Clearance of Latent HIV Infection:
214 Towards an HIV Cure symposium Melbourne Induction and Clearance of Latent HIV Infection: an Ex-Vivo Assessment of Immune Effectors using Cells from ART-treated Patients DM Margolis 1, C Garrido 1,
More informationHow to best manage HIV patient?
How to best manage HIV patient? 1 2 Treatment Treatment Failure success HIV therapy = a long life therapy Why do we want to change a suppressive ART? Side effect Comorbidities Reduce drug burden How to
More informationClinical Development of ABX464, drug candidate for HIV Functional Cure. Chief Medical Officer ABIVAX
Clinical Development of ABX464, drug candidate for HIV Functional Cure Jean-Marc Steens, MD Chief Medical Officer ABIVAX 1 DECLARATION OF CONFLICT OF INTEREST GSK ABIVAX 2 ABX464: Mechanism of Action ABX464
More informationInves)gación básica y curación del VIH- 1
Inves)gación básica y curación del VIH- 1 Javier Mar)nez- Picado (jmpicado@irsicaixa.es) 23 rd Conference on Retroviruses and Opportunis5c Infec5ons February 22-25, 2016 Boston, Massachuse8s UNIVERSITAT
More informationWorking Group#1: Trial Endpoints, Biomarkers & Definitions
Working Group#1: Trial Endpoints, Biomarkers & Definitions Forum HIV Cure Project: Focus on The Regulatory Pathway June 17, 2014 www.hivforum.org Comments from co-chairs john mellors and mike miller www.hivforum.org
More informationEngineered Immune-Mobilising Monoclonal T Cell Receptors for HIV Cure
Engineered Immune-Mobilising Monoclonal T Cell Receptors for HIV Cure Zoë Wallace Nuffield Dept. of Medicine University of Oxford 23 rd Annual Conference of the British HIV Association The HIV Reservoir
More informationHIV cure research: current strategies and challenges. current strategies to eliminate latently infected cells 2/10/2015
Viral load // HIV cure research: current strategies and challenges Sharon R Lewin Director, Doherty Institute for Infection and Immunity, The University of Melbourne, Consultant physician, The Alfred,
More informationNIH Public Access Author Manuscript J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2013 September 01.
NIH Public Access Author Manuscript Published in final edited form as: J Acquir Immune Defic Syndr. 2012 September 1; 61(1): 19 22. doi:10.1097/qai.0b013e318264460f. Evaluation of HIV-1 Ambiguous Nucleotide
More information23 rd CROI Report Back AETC/Community Consortium Harry W. Lampiris, MD Professor of Clinical Medicine, UCSF Chief, ID Section, Medical Service,
23 rd CROI Report Back AETC/Community Consortium Harry W. Lampiris, MD Professor of Clinical Medicine, UCSF Chief, ID Section, Medical Service, SFVAMC March 23, 2016 Boston, MA, February 22-25, 2016 Disclosures
More informationThe potential role of PD-1/PD-L1 blockade in HIV Remission and Cure Strategies
The potential role of PD-1/PD-L1 blockade in HIV Remission and Cure Strategies Stephen Mason Director, Discovery Virology Bristol-Myers Squibb Community Cure Workshop 2015 Sunday, Feb 22, 2015 Seattle,
More information5/19/2018. Disclosures. Lets start with definitions The cure continuum. Efforts and advances for the Cure
Efforts and advances for the Cure Pablo Tebas, MD Disclosures Consulting for Merck, Viiv and Gilead Write for uptodate 2 Lets start with definitions The cure continuum Long acting ART (Control of viremia
More informationCellular Immunity in Aging and HIV: Correlates of Protection. Immune Senescence
Cellular Immunity in Aging and HIV: Correlates of Protection Janet E. McElhaney, MD Professor of Medicine Allan M. McGavin Chair in Research Geriatrics University of British Columbia Vancouver, BC and
More informationTargeting latent HIV infection: on the road towards an HIV Cure
Towards an HIV Cure Pre-Conference Symposium 20 & 21 July 2012 Targeting latent HIV infection: on the road towards an HIV Cure David M. Margolis, MD Professor of Medicine Treatment Cure Prevention Prevention
More informationThe HIV Cure Agenda. CHIVA Oct Nigel Klein. Institute of Child Health and Great Ormond Street Hospital, London, UK
The HIV Cure Agenda CHIVA Oct 2016 Nigel Klein Institute of Child Health and Great Ormond Street Hospital, London, UK 2 How frequently is HIV cured? The Berlin patient Restriction of HIV entry CD4 is
More informationHIV Antibody Characterization for Reservoir and Eradication Studies. Michael Busch, Sheila Keating, Chris Pilcher, Steve Deeks
HIV Antibody Characterization for Reservoir and Eradication Studies Michael Busch, Sheila Keating, Chris Pilcher, Steve Deeks Blood Systems Research Institute University of California San Francisco, CA
More informationPathogenesis Update Robert F. Siliciano, MD, PhD
Pathogenesis Update Robert F. Siliciano, MD, PhD Professor of Medicine and Molecular Biology and Genetics Johns Hopkins University School of Medicine Investigator, Howard Hughes Medical Institute HIV-1
More informationPreventive and therapeutic HIV vaccines. Markus Bickel Infektiologikum Frankfurt
Preventive and therapeutic HIV vaccines Markus Bickel Infektiologikum Frankfurt No conflicts to declare Disclosures Background FAQ: by patients and colleagues Publication about promising results, especially
More informationEstablishment and Targeting of the Viral Reservoir in Rhesus Monkeys
Establishment and Targeting of the Viral Reservoir in Rhesus Monkeys Dan H. Barouch, M.D., Ph.D. Center for Virology and Vaccine Research Beth Israel Deaconess Medical Center Ragon Institute of MGH, MIT,
More informationInves&gación básica y curación del VIH-1
Inves&gación básica y curación del VIH-1 Javier Mar&nez-Picado 24 th Conference on Retroviruses and Opportunis6c Infec6ons UNIVERSITAT DE VIC Empezamos bien cart: How Early is Early Enough? Sáez-Cirion
More informationInnate and Cellular Immunology Control of Infection by Cell-mediated Immunity
Innate & adaptive Immunity Innate and Cellular Immunology Control of Infection by Cell-mediated Immunity Helen Horton PhD Seattle Biomedical Research Institute Depts of Global Health & Medicine, UW Cellular
More informationcure research HIV & AIDS
Glossary of terms HIV & AIDS cure research Antiretroviral Therapy (ART) ART involves the use of several (usually a cocktail of three or more) antiretroviral drugs to halt HIV replication. ART drugs may
More informationHIV viral load testing in the era of ART. Christian Noah Labor Lademannbogen, Hamburg
HIV viral load testing in the era of ART Christian Noah Labor Lademannbogen, Hamburg 1 Life expectancy of patients on ART Data from the UK Collaborative HIV Cohort (UK CHIC) Requirements: Early diagnosis
More informationHIV cure strategies: interventions, endpoints and ethics
HIV cure strategies: interventions, endpoints and ethics Professor Sharon R Lewin, FRACP, PhD, FAHMS Fourth Joint Conference of BHIVA with BASSH, April 17-20, Edinburgh International Conference Centre,
More informationJournal of Infectious Diseases Advance Access published July 11, Effect of Antiretroviral Therapy on HIV Reservoirs in Elite Controllers
Journal of Infectious Diseases Advance Access published July 11, 2013 1 Effect of Antiretroviral Therapy on HIV Reservoirs in Elite Controllers Tae-Wook Chun 1,6, J. Shawn Justement 1, Danielle Murray
More informationAbstract. Introduction
Histone Deacetylase Inhibitor Romidepsin Induces HIV Expression in CD4 T Cells from Patients on Suppressive Antiretroviral Therapy at Concentrations Achieved by Clinical Dosing Datsen George Wei 1, Vicki
More informationViral Reservoirs and anti-latency interventions in nonhuman primate models of SIV/SHIV infection
Viral Reservoirs and anti-latency interventions in nonhuman primate models of SIV/SHIV infection Koen Van Rompay California National Primate Research Center University of California Davis Outline Introduction
More informationEffect of 24 Week Intensification with a CCR5-Antagonist on the Decay of the HIV-1 Latent Reservoir
Effect of 24 Week Intensification with a CCR5-Antagonist on the Decay of the HIV-1 Latent Reservoir Laura Díaz 1, Carolina Gutiérrez 2, Carmen Page 2, Raquel Lorente 1, Beatriz Hernández-Novoa 2, Alejandro
More informationHIV Remission: Compound screening and optimization. Michael D. Miller
HIV Remission: Compound screening and optimization Michael D. Miller Can we drive HIV into remission in large numbers of patients? "George Bernard Shaw, speaking as an Irishman, summed up an approach to
More informationCombined IL-21 and IFNα treatment limits inflammation and delay viral rebound in ART-treated, SIV-infected macaques
Combined and IFNα treatment limits inflammation and delay viral rebound in ART-treated, SIV-infected macaques Mirko Paiardini Associate Professor, Emory University School of Medicine Yerkes National Primate
More informationPediatric HIV Cure Research
Pediatric HIV Cure Research HIV Cure Research Training Curriculum Pediatric HIV Cure Research Presented by: Priyanka Uprety,MSPH, PhD Laboratory of Deborah Persaud, MD Johns Hopkins University July 2016
More informationImmuno-modulatory Strategies for Reduction of HIV Reservoir Cells
Immuno-modulatory Strategies for Reduction of HIV Reservoir Cells H.T. Banks, Kevin B. Flores and Shuhua Hu Center for Research in Scientific Computation North Carolina State University Raleigh, NC 27695-8212
More informationHistone Deacetylase Inhibitors Impair the Elimination of HIV-Infected Cells by Cytotoxic T-Lymphocytes
Histone Deacetylase Inhibitors Impair the Elimination of HIV-Infected Cells by Cytotoxic T-Lymphocytes The MIT Faculty has made this article openly available. Please share how this access benefits you.
More informationTools to Monitor HIV Infection in 2013 and Beyond.
Tools to Monitor HIV Infection in 2013 and Beyond. Federico García, fegarcia@ugr.es Servicio de Microbiología Univ. Hospital San Cecilio Granada, Spain Outline Address clinical questions: Ultra sensitive
More informationProfessor Anna Maria Geretti
THIRD JOINT CONFERENCE OF BHIVA AND BASHH 2014 Professor Anna Maria Geretti Institute of Infection & Global Health, University of Liverpool 1-4 April 2014, Arena and Convention Centre Liverpool THIRD JOINT
More informationAdvances in HIV science and treatment. Report on the global AIDS epidemic,
HIV biomolecular advances and treatment updates David A Cooper National Centre in HIV Epidemiology and Clinical Research The University of New South Wales Sydney, Australia UNAIDS: global l HIV infections
More informationImmunodeficiency. (2 of 2)
Immunodeficiency (2 of 2) Acquired (secondary) immunodeficiencies More common Many causes such as therapy, cancer, sarcoidosis, malnutrition, infection & renal disease The most common of which is therapy-related
More informationTherapeutic Efficacy of a TLR7 Agonist for HBV Chronic Infection in Chimpanzees
Therapeutic Efficacy of a TLR7 Agonist for HBV Chronic Infection in Chimpanzees Robert Lanford 1, Bernadette Guerra 1, Deborah Chavez 1, Vida L. Hodara 1, Xubin Zheng 2, Grushenka Wolfgang 3, Daniel B.
More informationTowards an HIV Cure Pre-Conference Symposium 20 & 21 July 2012
Towards an HIV Cure Pre-Conference Symposium 20 & 21 July 2012 Your logo Natural control of HIV infection is associated with an isotype switched IgG antibody response to HIV Gag antigens in patients with
More informationAlternate Antibody-Based Therapeutic Strategies To Purge the HIV Cell Reservoir
Alternate Antibody-Based Therapeutic Strategies To Purge the HIV Cell Reservoir Giuseppe Pantaleo, M.D. Professor of Medicine Head, Division of Immunology and Allergy Executive Director, Swiss Vaccine
More informationBody & Soul. Research update, 25 October 2016
Body & Soul Research update, 25 October 2016 Updates from BHIVA conference on... Cure breakthrough or not? Long acting retrovirals what do they offer? When to start treatment asap post diagnosis? Media
More informationIAS 2016 Towards an HIV Cure Symposium Durban, South Africa.
Effect of vorinostat, hydroxychloroquine and maraviroc combination therapy on viremia following treatment interruption in individuals treated during acute HIV infection Eugène Kroon, Jintanat Ananworanich,
More informationAdditional Presentation Demonstrates Potential Mechanisms for Unprecedented HIV Reservoir Depletion by SB-728-T
September 8, 2014 Sangamo BioSciences Announces Presentation At ICAAC of New Clinical Data Demonstrating Sustained Functional Control of Viremia in Multiple HIV- Infected Subjects Treated with SB-728-T
More informationBEAT-HIV Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy
BEAT-HIV Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy We are pleased to announce that the National Institutes of Health (NIH) has awarded nearly $23 million to co-principal
More informationDual approach to HIV-1 cure: Activation of latency and restoration of exhausted virus-specific T cell function
Dual approach to HIV-1 cure: Activation of latency and restoration of exhausted virus-specific T cell function Stephen Mason Director, Discovery Virology Bristol-Myers Squibb Disclosure: Paid employee
More informationInhibition of HIV-1 Integration in Ex Vivo-Infected CD4 T Cells from Elite Controllers
JOURNAL OF VIROLOGY, Sept. 2011, p. 9646 9650 Vol. 85, No. 18 0022-538X/11/$12.00 doi:10.1128/jvi.05327-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Inhibition of HIV-1 Integration
More informationI declare that I have no financial conflicts of interest
I declare that I have no financial conflicts of interest Cytotoxic T-Lymphocytes Eliminate Defective HIV Proviruses Without Impacting Infectious Reservoirs R. Brad Jones Assistant Professor The George
More informationTherapeutic strategies for immune reconstitution in acquired immunodeficiency syndrome
30 1, 1, 2, 3 1. ( ), 201508; 2., 200040; 3., 200032 : ( AIDS) ( HIV) 20 90,,,,,, AIDS, CD4 + T ( CTL), HIV, : ; ; Therapeutic strategies for immune reconstitution in acquired immunodeficiency syndrome
More informationT-Pharmacytes for the Targeted Eradication of HIV Reservoirs
T-Pharmacytes for the Targeted Eradication of HIV Reservoirs Walker Lab Rachel O Connor Alicja Trocha Dan Karel Irvine Lab Stefanie Mueller Humanized Mouse Core Vlad Vrbanac Andy Tager Todd Allen Darrell
More informationHIV-1 Eradication: Early Trials (and Tribulations)
Feature Review HIV-1 Eradication: Early Trials (and Tribulations) Adam M. Spivak 1 and Vicente Planelles 2, * Antiretroviral therapy (ART) has rendered HIV-1 infection a manageable illness for those with
More informationAlexander O. Pasternak, Mirte Scherpenisse, Ben Berkhout
Cell-associated HIV-1 unspliced to multiply spliced RNA ratio at 12 weeks ART correlates with markers of immune activation and apoptosis and predicts the CD4 + T-cell count at 96 weeks ART Alexander O.
More informationMechanisms of antagonism of HIVspecific CD4+ T cell responses BSRI
Mechanisms of antagonism of HIVspecific CD4+ T cell responses BSRI Problems Virus escape from immune recognition Antagonism of T cell responses Peptide-MHC-TCR interaction T cell antagonism Variants of
More informationRoger Shapiro, MD, MPH Harvard TH Chan School of Public Health Botswana-Harvard Partnership May 2018
A Clinical Trial to Evaluate the Impact of Broadly Neutralizing Antibodies VRC01LS and 10-1074 on Maintenance of HIV Suppression in a Cohort of Early-Treated Children in Botswana Roger Shapiro, MD, MPH
More informationComparison of latent HIV-1 reactivation in multiple cell model systems
Comparison of latent HIV-1 reactivation in multiple cell model systems Celsa A. Spina, Jenny Anderson, Nancie M. Archin, Alberto Bosque, Jonathan Chan, Marylinda Famiglietti, Warner C. Greene, Angela Kashuba,
More informationProfessor Mark Bower Chelsea and Westminster Hospital, London
Professor Mark Bower Chelsea and Westminster Hospital, London Cancer immunotherapy & HIV Disclosures: None Lessons for oncology from HIV Awareness and advocacy Activism Rational drug design Prescribing
More informationHIV-DNA: nuovo marcatore virologico. Metodiche a confronto per la quantificazione di HIV-DNA
HIV-DNA: nuovo marcatore virologico Metodiche a confronto per la quantificazione di HIV-DNA Maria Carla Re Laboratorio Retrovirus e Agenti infettivi HIV correlati UO di Microbiologia, Università di Bologna
More informationImmunologic Failure and Chronic Inflammation. Steven G. Deeks Professor of Medicine University of California, San Francisco
Immunologic Failure and Chronic Inflammation Steven G. Deeks Professor of Medicine University of California, San Francisco Plasma HIV RNA (log) 6 5 4 3 2 52 year old HIV+/HCV+ man presents with symptomatic
More informationQuantification of HBV, HCV genotype and HIV subtype panels
Quantification of HBV, HCV genotype and HIV subtype panels Harry van Drimmelen 1,2, Wim Quint 2, Nico Lelie 3 and the international NAT study group 1. Biologicals Quality Control, 2. DDL Diagnostic Laboratory,
More informationImmune correlates of protection from congenital cytomegalovirus after primary infection in pregnancy
Laboratori Sperimentali di Ricerca, Fondazione IRCCS Policlinico San Matteo, Pavia, Italia Immune correlates of protection from congenital cytomegalovirus after primary infection in pregnancy Daniele Lilleri
More informationRapid perforin upregulation directly ex vivo by CD8 + T cells is a defining characteristic of HIV elite controllers
Rapid perforin upregulation directly ex vivo by CD8 + T cells is a defining characteristic of HIV elite controllers Adam R. Hersperger Department of Microbiology University of Pennsylvania Evidence for
More informationBRIEF REPORT METHODS. Twenty-seven HIV-infected individuals receiving ART for a median of 2 years were included in this study (Table 1).
BRIEF REPORT Effect of Histone Deacetylase Inhibitors on HIV Production in Latently Infected, Resting CD4 + T Cells From Infected Individuals Receiving Effective Antiretroviral Therapy Jana Blazkova, 1,a
More informationHIV Pathogenesis and Natural History. Peter W. Hunt, MD Associate Professor of Medicine University of California San Francisco
HIV Pathogenesis and Natural History Peter W. Hunt, MD Associate Professor of Medicine University of California San Francisco Learning Objectives Describe key features of HIV pathogenesis and natural history
More informationThe relation between HIV- 1 integration and latency
The relation between HIV- 1 integration and latency Linos Vandekerckhove HIV translational research, Ghent Department of General Internal Medicine, Infectious Diseases and Psychosomatic Medicine University
More informationDEBATE ON HIV ENVELOPE AS A T CELL IMMUNOGEN HAS BEEN GAG-GED
DEBATE ON HIV ENVELOPE AS A T CELL IMMUNOGEN HAS BEEN GAG-GED Viv Peut Kent Laboratory, University of Melbourne, Australia WHY ENVELOPE? Env subject to both humoral and cellular immune responses Perhaps
More informationRationale for therapy at PHI
Rationale for therapy at PHI Immunological: Interfere with pathogenesis Preserve HIV-specific CD4+ T-help Reduce T-cell activation Virological: Prevent or reduce seeding of reservoirs Affect viral set
More informationDevelopment of 5 LTR DNA methylation of latent HIV-1 provirus in cell line models and in long-term-infected individuals
Trejbalová et al. Clinical Epigenetics (2016) 8:19 DOI 10.1186/s13148-016-0185-6 RESEARCH Development of 5 LTR DNA methylation of latent HIV-1 provirus in cell line models and in long-term-infected individuals
More informationScott Abrams, Ph.D. Professor of Oncology, x4375 Kuby Immunology SEVENTH EDITION
Scott Abrams, Ph.D. Professor of Oncology, x4375 scott.abrams@roswellpark.org Kuby Immunology SEVENTH EDITION CHAPTER 13 Effector Responses: Cell- and Antibody-Mediated Immunity Copyright 2013 by W. H.
More informationEBV Infection and Immunity. Andrew Hislop Institute for Cancer Studies University of Birmingham
EBV Infection and Immunity Andrew Hislop Institute for Cancer Studies University of Birmingham EBV Introduction Large ds DNA virus Spread by saliva contact Lifelong infection Predominantly B-lymphotropic
More informationAddressing key gaps in cure research through identification and treatment of hyperacute HIV infection in a resource-limited setting
Addressing key gaps in cure research through identification and treatment of hyperacute HIV infection in a resource-limited setting Thumbi Ndung u, BVM, PhD KwaZulu-Natal Research Institute for Tuberculosis
More informationInvited Review CROI 2018: Advances in Basic Science Understanding of HIV
Invited Review CROI 2018: Advances in Basic Science Understanding of HIV Mario Stevenson, PhD The conference on Retroviruses and Opportunistic Infections represents the most important venue for the dissemination
More informationHIV acute infections and elite controllers- what can we learn?
HIV acute infections and elite controllers- what can we learn? Thumbi Ndung u, BVM, PhD KwaZulu-Natal Research Institute for Tuberculosis and HIV (K-RITH) and HIV Pathogenesis Programme (HPP), Doris Duke
More information19-Sept Quantifying and reservoirs in an HIV cure setting. One day symposium. Latest news on European HIV Cure trials
Quantifying and characterizing HIV reservoirs in an HIV cure setting One day symposium Latest news on European HIV Cure trials Optional three day workshop 20-22 Sept 2016 19-Sept-2016 HCRC Ghent University
More informationAntigen Presentation and T Lymphocyte Activation. Abul K. Abbas UCSF. FOCiS
1 Antigen Presentation and T Lymphocyte Activation Abul K. Abbas UCSF FOCiS 2 Lecture outline Dendritic cells and antigen presentation The role of the MHC T cell activation Costimulation, the B7:CD28 family
More informationCan we eradicate HIV?
Can we eradicate HIV? New therapeutic strategies towards a cure Laurence COLIN Laboratory of Molecular Virology University of Brussels Belgium The success story of HAART encountered solid barriers to virus
More information